• Mashup Score: 0

    November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and can lower the risk of death or major bleeding by 31 percent.  These are findings from a new study led by researchers from the Icahn School of Medicine at Mount Sinai. This is the…

    Tweet Tweets with this article
    • @DAICeditor @MountSinaiNYC #Bivalirudin is a safer and more effective #anticoagulant than #heparin for treating patients with the most serious type of #heartattacks who undergo urgent #PCI, and can lower the risk of death or major bleeding by 31%: https://t.co/aPpKKg5tUJ

  • Mashup Score: 2

    In COVID-19 ICU survivors the authors identified treatment with low- molecular-weight heparin as a predictor of improved physical component of QoL at 6 months.

    Tweet Tweets with this article
    • Following up 125 ICU #COVID19 survivors for 6 months. LMW #heparin treatment in the ICU was the only modifiable factor associated with an improved physical component of quality of life. 🔗 https://t.co/MVE1JhIAKw #FOAMcc #MicroCLOTS https://t.co/ypNmOGb6XX

  • Mashup Score: 4

    In this issue of Blood, Singh et al1 examined the interaction of heparin, danaparoid, fondaparinux, and argatroban with antibodies against platelet factor 4 (PF

    Tweet Tweets with this article
    • Editorial in @BloodJournal discussing the paper which showed that in vitro studies suggested that heparin may have been the best anticoagulant to use in #VITT. https://t.co/Qqze1pamPc #heparin https://t.co/Wt8lRgQqeH